Content area

Full Text

Headnote

Abstract

Purpose To compare transurethral resection only with transurethral resection plus early instillational treatment for non-invasive (Ta,T1) bladder cancer.

Patients and methods Between 2000-april 2005, 1 30 patients with Ta and T1 bladder cancers were included in this study. The patients were divided in two groups:

Group A including 81 patients who were treated (2000-2002) with transurethral resection of the bladder tumours CTURB). Follow up: 48-80 months (mean 73,4).

Goup B including 50 patients with TURB, 1 instillation with 50 mg of Epirubicin in the first 6 po hours. Follow up 2460 months (mean 43). The patients refused, ignored or were not fit for other adjuvant treatment. The follow up were performed every 3 months in the first year, 4 months in the 2nd year, 6 months in the 3-th and 4 -th year, than every year.

Results In group A, the percent of recurrencies according to the risk categories are: 30%, 37,5%, 58%. The total recurrence in group A is 44,4%. In group B, the percent of recurrencies are: 0%, 25,8%, 75%. The total recurrence is 34%. The benefit of 1 instillation with Epirubicin post-TURB is 8,2%, particulary for low risk group is 30. The progression rate in group A are: 0%, 12,5%, 29%. The global progression is 17,2%. In the group B, the progression rate is: 0%, 10%, 25%. The global progression is 12%.

Conclusions The global benefit regarding recurrence is 10,4%. The study indicated a significant benefit in favor of the early instillational treatment in the low and intermediat risk group, reducing the percent of tumor recurrence Regarding progression there is a benefit of 5,2%.

Key words: noninvasive bladder cancer, early instillation , recurrence, progression.

Headnote

Abrevieri

TURV - transuretrorezecZie

E1po - o dozä de Epirubicin imédiat postoperator

E15 - tratament instilaÇional cu Epirubicin

(4 säptämänale + 1 1 lunare)

R -recidiva

P -progresie

BCG - Baci! Calmette-Guerin

Rezumat

Scop Stabilirea impactului instila^iei cu citostatic în primele 6 ore post-operator, în evoluZia post-TURV a tumorilor vezicale noninvazive.

Pacienji si metodà Un numär de 131 de pacienZi, trataZi de cätre autor, între ianuarie 2000-aprilie 2005 au intrat în acest studiu. PacienZii au fost ímparZiZi în douä loturi:

A. format din 81 de pacienZi trataZi prin TURV

B. format din 50 de pacienZi...

Show less